CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
Other Income/Expenses (Net) Over TimeContracting
Percentile Rank58
3Y CAGR+37.4%
5Y CAGR-29.3%
Studio
Year-over-Year Change

Net other income and expenses outside core operations

3Y CAGR
+37.4%/yr
vs -28.2%/yr prior
5Y CAGR
-29.3%/yr
Recent acceleration
Acceleration
+65.5pp
Accelerating
Percentile
P58
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$5.23M-26.3%
2024$7.10M-27.6%
2023$9.81M+386.0%
2022$2.02M+1073.3%
2021$172000.00-99.4%
2020$29.63M+260.0%
2019$8.23M+8.7%
2018$7.57M+186.1%
2017$2.65M+296.9%
2016$667000.00-